strengthpeptide
All news
NewsPfizerGLP-1monthly dosing

Pfizer monthly GLP-1 hits 12.3% weight loss in Phase 2b

Pfizer's PF-08653944 produced up to 12.3% placebo-adjusted weight loss at 28 weeks in VESPER-3, validating monthly-dosing GLP-1 with 10 Phase 3 trials planned for 2026.

May 29, 2026 · 3 min read

Pfizer's PF-08653944 (previously MET-097i) — an ultra-long-acting injectable GLP-1 receptor agonist — produced up to 12.3% placebo-adjusted weight loss at 28 weeks in the Phase 2b VESPER-3 trial, with the headline being that the weight loss continued without plateau after patients transitioned from weekly to monthly dosing. Pfizer announced plans to advance 10 Phase 3 trials in 2026 across once-weekly and once-monthly formulations.

The monthly-dosing demonstration matters: if it holds through Phase 3, it changes the practical experience of GLP-1 therapy from weekly injections to monthly ones — a meaningful adherence and lifestyle improvement.

What happened

The VESPER-3 trial enrolled approximately 54 participants per arm across five arms (placebo + four dosing regimens), with a 64-week total duration and primary results reported at week 28. The dosing structure was unusual: weekly titration for 12 weeks, then transition to monthly dosing through week 28.

Headline results:

  • Primary endpoint met: statistically significant weight reduction
  • Up to 12.3% placebo-adjusted weight loss at week 28
  • Arms planned for Phase 3 produced 10% and 12.3% weight loss
  • Robust and continuous weight loss after switching to monthly dosing, with no plateau observed
  • Safety profile consistent with the GLP-1 class — predominantly mild-to-moderate GI adverse events
  • Zero discontinuations due to adverse events in the placebo group

Pfizer is planning 10 Phase 3 trials of PF'3944 in 2026, covering once-weekly and once-monthly formulations across diverse patient populations and comorbidities. This is an aggressive Phase 3 schedule that signals Pfizer's intent to claim significant market share in the GLP-1 space.

Why it matters

For the GLP-1 and strength-peptide community, the monthly-dosing angle is the central story:

Adherence dynamics shift. Weekly injections require sustained behavior change. Monthly injections look more like quarterly birth control or LARC adherence patterns. The dropout rates from GLP-1 therapy may improve substantially with monthly dosing.

Pharmacokinetic flexibility expands. A drug that maintains effect across a month is operating at very different plasma profile dynamics than weekly semaglutide. This may produce different efficacy and side-effect profiles in subtle ways worth tracking.

Competitive landscape sharpens. Semaglutide and tirzepatide dominate the weekly market. Pfizer's monthly entrant — if Phase 3 confirms — opens a meaningful differentiation lane. Novo Nordisk and Lilly will respond with their own long-acting candidates.

Off-label and compounded availability typically follows approval timing. A 2027–2028 FDA approval for monthly Pfizer GLP-1 would shift the compounded market about 12–18 months later. For strength-peptide users who currently navigate weekly semaglutide compounds, a monthly option could simplify protocols.

For the broader GLP-1 frame see tirzepatide vs semaglutide for body composition and semaglutide + peptide stack: protecting lean mass on GLP-1.

What to watch

Several markers over the next 18–24 months:

  • Phase 3 readouts — first PF-08653944 Phase 3 data likely 2027 given the trial duration
  • Direct head-to-head comparisons — whether Pfizer designs trials directly comparing monthly PF-08653944 to weekly semaglutide or tirzepatide
  • Lean mass preservation data — Phase 3 substudies should clarify whether monthly dosing produces different body composition outcomes than weekly
  • Pricing strategy — Pfizer entering GLP-1 with established manufacturing capacity may produce more competitive pricing than the current duopoly
  • Other monthly candidates — Novo Nordisk and Lilly's own long-acting programs will move

The broader retatrutide / tirzepatide / pemvidutide pipeline (see our retatrutide TRIUMPH-1 coverage and pemvidutide IMPACT MASH coverage) is producing readouts at a faster pace than most users can absorb. The GLP-1 / dual-agonist / triple-agonist family is now the most active drug development category in metabolic medicine.

Sources

Sources